Robert L. Judd, PhD

Dr. Judd’s major research interests center around new treatments for type 2 diabetes. In addition, his lab is conducting investigations into the metabolic ameliorations in glucose and fat metabolism which results in the physiological expression of type 2 diabetes. These current investigations are focused on cytokines secreted from adipose tissue (termed "adipokines") and their role on whole body energy metabolism.  Specifically, Dr. Judd's laboratory is focused on the impact of niacin on adipokine gene expression and secretion.  [Research is or has been supported by the Pharmaceutical Research and Manufacturers of American Foundation (PhRMA), American Association of Colleges of Pharmacy (AACP), American Diabetes Association (Louisiana and Minnesota Affiliates), National Institutes of Health (NIH), Diabetes Trust Foundation, and Diabetes Action Research and Education Foundation.]

Boshell Diabetes and Metabolic Diseases Research Programs

Jim Fyffe Diabetes Research Fund

Hafiz S, Dennis J, Schwartz D, Judd RL, Tao Y, Khazal K, Akingbemi B, Mu X, Abdel-Mageed A, Morrison E and Mansour M. (2012) Expression of mealnocortin receptors in human prostate cancer cell lines:  MC2R activation by ACTH increases prostate cancer cell proliferation. International Journal of Oncology (In Press)

Wanders D, Graff EC and Judd RL.  Effects of high fat diet on GPR109A and GPR81 gene expression. Biochemical and Biophysical Research Communications 425:278-283, 2012.

Wooldridge A, Edwards HA, Plaisance EP, Applegate R, Taylor D, Taintor J, Zhong Q and Judd, RL.  High molecular weight adiponectin in horses.  American Journal of Veterinary Research 73(8):1230-1240, 2012.

Pfaehler A, Nanjappa MK, Coleman ES, Mansour M, Wanders D, Plaisance EP, Judd RL and Akingbemi BT.  Regulation of adiponectin secretion by soy isoflavones has implication for endocrine function of the testis.  Toxicology Letters  209:78-85, 2012.

Wanders D and Judd RL.  Future of GPR109A agonists in the treatment of dyslipidemia.  Diabetes, Obesity and Metabolism 13(8):685-691, 2011.

Godwin L, Pilkerton ME, Deal KS, Wanders D, Judd RL and Easley CJ.  A passively operated microfluidic device for stimulation and secretion sampling of single pancreatic islets.  Analytical Chemistry  83(18):7166-7172, 2011.

Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, Dennis J, Bartol FF, Hazi A, Napier I, Abdel-Mageed AB.  Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.  Intl J Oncology 38(2):537-546, 2011.

Plaisance EP, Lukasova M, Offermanns S, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A Receptor. American Journal of Physiology-Endocrinology and Metabolism296:E549-E558, 2009.

Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 57:404-409, 2008.

Wang J, Wernette C, Judd RL, White BD. Guanethidine treatment does not block the ability of central leptin administration to decrease blood glucose concentrations in streptozotocin-induced diabetic rats, Journal of Endocrinology 198(3):541-854, 2008.

Mansour M, Goyal HO, Braden TD, Dennis JC, Schwartz D, Judd RL, Bartol FF, Coleman E, Morrison EE. Activation of penile pro-adipogenic peroxisome proliferator-activated receptor with an estrogen:  interaction with estrogen receptor α during postnatal development. PPAR Research 2008:651419, 2008.

Brunson BL, Zhong Q, Clarke KJ, Bedi D, Braden TD, Van Santen E, Judd RL. Characterization of adiponectin in the dog. American Journal of Veterinary Research 68 (1):57-62, 2007.

Ding Y, Zuo R, Judd RL, Zhong, J. Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats. Endocrine 30:121-127, 2006.

Bedi D, Clarke KJ, Dennis JC, Zhong Q, Brunson BL, Morrison EE, Judd RL. Endothelin-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5-bisphosphate/actin-dependent mechanism. Biochemical and Biophysical Research Communications 345:332-339, 2006.

Ding Y, Zuo R, Judd RL, Zhong J. Effects of gender differences on cardiac myocyte dysfunction in streptozotocin-induced diabetic rats. Endocrinology 29(1):135-141, 2006.

Ding Y, Zuo R, Judd RL, Schwartz DD, Zhong J. Contribution of endothelin-1 in cardiac myocyte dysfunction in type 1 diabetic rats. J Card-Renal Res 1:23-32, 2005.

Dennis JC, Coleman ES, Swyers SE, Moody SW, Wright JC, Judd RL, Morrison EE. Changes in mitotic rate and GFAP expression in the primary olfactory acis of Streptozotocin-induced diabetic rats. J Neurocytology 34:3-10, 2005.

Coleman ES, Judd RL, Hoe LL, Dennis JC, Posner PP. Effects of diabetes mellitus on astrocyte GFAP and glutamate transporters in the CNS. Glia 48:166-178, 2004.

Clarke KJ, Zhong Q, Schwartz DD, Coleman ES, Kemppainen RJ, Judd RL. Regulation of adiponectin secretion by endothelin-1. Biochemical and Biophysical Research Communications 312:945-949, 2003.

Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL. Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 296:383-387, 2002.

Lin CY, Higginbotham DH, Judd RL, White BD. Central leptin increases insulin sensitivity and normalizes blood glucose concentrations in streptozotocin-treated diabetic rats.  American Journal of Physiology-Endocrinol Metab 282:E1084-E1091, 2002.

Raman P, Judd RL. Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis. European Journal of Pharmacology 409(1):19-29, 2000.

American Diabetes Association

Juvenile Diabetes Research Foundation International

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)